The combination treatment resulted in significantly reduced tumor growth compared with AZD1152 (p < 0.001) or anti-CTLA4 (p = 0.019) alone (Fig. 4b) and significantly improved survival (p = 0.002; Fig. 4c). The gene discussed is CTLA4; the disease is neoplasm.